Abstract:Lung cancer is the commonest cancer killer worldwide. Tyrosine-kinase inhibitors (TKI) are novel agents in the treatment of this cancer. However, their efficacy is impaired by the rapid development of drug-resistance through a variety of mechanisms. Here, we will discuss resistance to the first-generation EGFR inhibitors (e.g. Erlotinib) and SRC inhibitors (e.g. Dasatinib). The principal mechanism of resistance to first-generation EGFR inhibitors is the appearance of the T790M receptor mutation. While the reason for resistance was proposed to be changes in affinity of the receptor for ATP, our metabolomics analysis additionally revealed that resistance is associated with decreased cellular levels of glutathione (GSH), a direct consequence of the T790M mutation. This occurred because of decreased SQSTM1/NRF2-mediated transcription of GSH synthesising enzymes in cell lines and clinical samples with T790M-EGFR. We demonstrate that increasing GSH levels in resistant cells re-sensitises these to first-generation EGFR inhibitors in vitro and in vivo. As compounds exist in the clinic to achieve this, our finding may have profound therapeutic and economic consequences. Src family kinases (SFK) are commonly overexpressed or hyperactivated in lung cancer cell lines and clinical samples. However, despite their on-target efficacy, SRC inhibitors have failed to prevent tumour growth and improve patients' survival in multiple clinical trial. Here we show that this failure is associated with the induction of autophagy in treated cells that prevents these compounds from triggering apoptosis cell death. Targeting autophagy, either genetically or using our novel small-molecule inhibitor, C1A, sensitises lung cancer cell lines to Dasatinib both in vitro and in vivo by unlocking the apoptotic response. These findings propose new combinational therapeutic strategies that could resurrect the use of SRC inhibitors in the treatment of lung cancer.

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.

EGFR inhibitors and autophagy in cancer treatment

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Targeting EGFR‐mediated Autophagy As a Potential Strategy for Cancer Therapy

Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC

EGFR-mediated Autophagy in Tumourigenesis and Therapeutic Resistance

Autophagy is a Therapeutic Target in Anticancer Drug Resistance

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Autophagy as a therapeutic target in pancreatic cancer

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer

Key Autophagic Targets and Relevant Small-Molecule Compounds in Cancer Therapy.

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma

Targeting Non-Canonical Autophagy Overcomes Erlotinib Resistance in Tongue Cancer.

Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy

Resistance to Tyrosine Kinase-Targeted Therapy in Lung Cancer: Autophagy and Metabolic Changes

Mtor Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations.

Pro-survival autophagy and cancer cell resistance to therapy

Autophagy, an Achilles’ Heel AKTing Against Cancer?